Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**1,3-bis-(3,4,5-trimethoxyphenyl)-2,3-epoxypropanone** is a synthetic small molecule belonging to the class of chalcone epoxides. It exhibits significant cytotoxic activity against various human cancer cell lines, with an average GI50 (growth inhibition by 50%) of 14.1 µM across the NCI 60-cell-line panel. The compound induces cell cycle arrest at the G2/M phase and promotes apoptosis in cancer cells, demonstrated by marked effects in pancreatic cancer cell lines. Mechanistically, it disrupts microtubule dynamics by interfering with tubulin polymerization, likely through alkylation of β-tubulin at cysteine 354 following epoxide ring opening. Covalent modification of proteins via reaction with nucleophilic thiols is a central feature of its action. The compound has not reached development as a marketed drug and remains a research chemical with demonstrated anticancer activity in preclinical models[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1,3-bis-(3,4,5-trimethoxyphenyl)-2,3-epoxypropanone.